In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...
A spin-out from the University of Edinburgh in Scotland is already equipped with 15 million pounds ($19 million) in seed ...
Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for ...
What have we learned about Alzheimer’s disease over the last five years? Major breakthroughs have been made recently in the research and development of this complex, memory-robbing disease.
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...
Philips has secured an FDA clearance for what it describes as the world’s first imager to combine spectral CT with ...
Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...
Last month, the NIH announced that it had found evidence of research misconduct by Eliez | This week on "The Top Line," we ...
Two industry veterans are taking the reins at Apriori Bio and Valo Health, biotechs backed by VC firm Flagship Pioneering. Craig Williams has been promoted to CEO-partner at Flagship and is now CEO of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback